Indivior Pharmaceuticals is seeing its stock rise 15.6% year to date, outperforming an industry decline of 6.8%, as its once-monthly injectable opioid use disorder treatment Sublocade drives growth. Since its 2018 launch, more than 500,000 U.S. patients have received Sublocade, and management expects U.S. dispense-unit growth to accelerate to the mid-teens in 2026. The company has discontinued internal development of pipeline drugs INDV-6001 and INDV-2000 to focus on higher-value opportunities and is executing a cost-optimization program. Indivior currently holds a Zacks Rank #1 (Strong Buy), with 2026 and 2027 earnings per share estimates unchanged at $4.05 and $4.27, respectively.
Indivior PLC Ordinary SharesSublocade drives growth with over 500,000 patients and expected mid-teens dispense-unit growth in 2026.
Liquidia Technologies Inc
Amarin Corporation PLC
Immunocore Holdings Ltd